Betacoronavirus; Coronavirus Infections/epidemiology; Hemophilia A/therapy; Hemophilia B/therapy; Pandemics; Pneumonia, Viral/epidemiology; Anti-Inflammatory Agents, Non-Steroidal/adverse effects; Antibodies, Bispecific/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; COVID-19; Clinical Trials as Topic; Comorbidity; Continuity of Patient Care; Contraindications, Drug; Coronavirus Infections/blood; Coronavirus Infections/complications; Coronavirus Infections/prevention & control; Delivery of Health Care; Disease Management; Drug Substitution; Factor IX/supply & distribution; Factor IX/therapeutic use; Factor VIII/supply & distribution; Factor VIII/therapeutic use; Fibrinolytic Agents/adverse effects; Fibrinolytic Agents/therapeutic use; Genetic Therapy; Health Resources/supply & distribution; Hemophilia A/complications; Hemophilia A/epidemiology; Hemophilia B/complications; Hemophilia B/epidemiology; Hemorrhage/etiology; Hemorrhage/prevention & control; Humans; Pandemics/prevention & control; Pneumonia, Viral/blood; Pneumonia, Viral/complications; Pneumonia, Viral/prevention & control; Professional-Patient Relations; SARS-CoV-2; Social Media; Telemedicine; Thrombophilia/etiology